Usama Wissa
Cornell University
7 Papers
19 Citations
Usama Wissa is an academic researcher from Cornell University. The author has contributed to research in topics: Transplantation & Medicine. The author has an hindex of 5, co-authored 7 publications. Previous affiliations of Usama Wissa include NewYork–Presbyterian Hospital.
Chat about Author
Papers
Effectiveness and Safety of Tocilizumab, an Anti–Interleukin-6 Receptor Monoclonal Antibody, in a Patient With Refractory GI Graft-Versus-Host Disease
Usama Gergis,Jon E. Arnason,Rhonda K. Yantiss,Tsiporah B. Shore,Usama Wissa,Eric J. Feldman,Thasia G. Woodworth +6 more
TL;DR: A 22-year-old white man with idiopathic, severe aplastic anemia underwent an allogeneic stem-cell transplantation from a human leukocyte antigen–matched sibling and experienced CMV and Epstein-Barr virus reactivation and proven pulmonary Aspergillosis, and he became narcotic dependent.
39
A Phase I Study of CPX-351 in Combination with Busulfan and Fludarabine Conditioning and Allogeneic Stem Cell Transplantation in Adult Patients with Refractory Acute Leukemia
Usama Gergis,Gail J. Roboz,Tsiporah B. Shore,Ellen K. Ritchie,Sebastian Mayer,Usama Wissa,Marshall McKenna,Paul J. Christos,Roger N. Pearse,Tomer M Mark,Joseph M. Scandura,Koen van Besien,Eric J. Feldman +12 more
TL;DR: This phase I study evaluated the maximal tolerated dose of CPX-351 when administered sequentially with allogeneic hematopoietic stem cell transplantation (HSCT) in patients with refractory acute leukemia and suggested that a phase II trial should incorporate CPx-351 120 U/m(2) × 3 dosing on schedule B.
20
Are low-intensity induction strategies better for older patients with acute myeloid leukemia?
Gail J. Roboz,Usama Wissa,Ellen K. Ritchie,Usama Gergis,Sebastian Mayer,Joseph M. Scandura,Paul J. Christos,Eric J. Feldman +7 more
TL;DR: There was no significant difference in overall survival between patients initially treated with a low-intensity regimen compared to those receiving standard-intensity induction and there were no differences in 30- or 60-day mortality between the two groups.
10
High-Risk Myelodysplastic Syndromes: Chemotherapy, Transplantation, and Beyond
Usama Gergis,Usama Wissa +1 more
TL;DR: Current therapeutic options should view the hypomethylating agents as a way to optimize disease response before (and possibly after) HCT, and these agents offer only a modest survival benefit.
8